Protara Therapeutics is trading 5.23% lower at $2.62 on October 13, 2026; no clear company-specific announcement explaining the decline has surfaced.
- A scheduled Cantor meeting was reported, but no evidence linked it to the move.
- Biotech sector pressure included XBI down 2.01%. It may be contributing, but does not fully explain Protara Therapeutics’ larger decline.
- Earlier trading data showed below-average volume, though it predates the current quote.